Sublingual Misoprostol versus Intramuscular Oxytocin for Prevention of Postpartum Hemorrhage in Uganda: A Double-Blind Randomized Non-Inferiority Trial

Simple item page
dc.contributor.authorAtukunda, Esther C.
dc.contributor.authorObua, Celestino
dc.contributor.authorMugyenyi, Godfrey R.
dc.contributor.authorTwagirumukiza, Marc
dc.contributor.authorAgaba, Amon G.
dc.date.accessioned2025-05-07T19:23:00Z
dc.date.available2025-05-07T19:23:00Z
dc.date.issued2014-11-04
dc.description.abstractPostpartum hemorrhage (PPH) is a leading cause of maternal death in sub-Saharan Africa. Although the World Health Organization recommends use of oxytocin for prevention of PPH, misoprostol use is increasingly common owing to advantages in shelf life and potential for sublingual administration. There is a lack of data about the comparative efficacy of oxytocin and sublingual misoprostol, particularly at the recommended dose of 600 µg, for prevention of PPH during active management of labor.
dc.identifier.citationAtukunda, E. C., Siedner, M. J., Obua, C., Mugyenyi, G. R., Twagirumukiza, M., & Agaba, A. G. (2014). Sublingual misoprostol versus intramuscular oxytocin for prevention of postpartum hemorrhage in Uganda: a double-blind randomized non-inferiority trial. PLoS medicine, 11(11), e1001752.
dc.identifier.otherhttps://doi.org/10.1371/journal.pmed.1001752
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/11494
dc.language.isoen
dc.publisherPLoS medicine
dc.titleSublingual Misoprostol versus Intramuscular Oxytocin for Prevention of Postpartum Hemorrhage in Uganda: A Double-Blind Randomized Non-Inferiority Trial
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
file (2).pdf
Size:
554.48 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences